Supriya Lifescience Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Supriya Lifescience Ltd is ₹ 978.65 as of 12 Jun 15:30 . The P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 yearsThe P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 yearsThe Market Cap of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 14.94 crore on March 2025 to ₹ 14.94 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Supriya Lifescience Ltd for the Mar '26 is ₹ 280.01 crore as compare to the Dec '25 revenue of ₹ 209.05 crore. This represent the growth of 33.94% The revenue of Venmax Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 4.04 crore as compare to the Dec '25 revenue of ₹ 1.62 crore. This represent the growth of 149.38% The ebitda of Supriya Lifescience Ltd for the Mar '26 is ₹ 101.1 crore as compare to the Dec '25 ebitda of ₹ 74.24 crore. This represent the growth of 36.18% The ebitda of Venmax Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 0.11 crore as compare to the Dec '25 ebitda of ₹ 0.04 crore. This represent the growth of 175% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 74.23 crore over 8 quarters. This represents a CAGR of 28.95% The net profit of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0.01 crore to ₹ 0.11 crore over 8 quarters. This represents a CAGR of 231.66% The Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 yearsThe Dividend Payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

About Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998.
The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'.
Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc. The Company is developing the oncology products in R&D.

FAQs for the comparison of Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Supriya Lifescience Ltd or Venmax Drugs & Pharmaceuticals Ltd?

Market cap of Supriya Lifescience Ltd is 7,876 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 23 Cr

What are the key factors driving the stock performance of Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd?

The stock performance of Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd?

As of June 14, 2026, the Supriya Lifescience Ltd stock price is INR ₹978.65. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹20.0.

How do dividend payouts of Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Supriya Lifescience Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.